Get the Stockscreener App
5.85
2.82%
-0.17
After Hours:
5.94
0.09
+1.54%
Cybin Inc stock is traded at $5.85, with a volume of 360.14K.
It is down -2.82% in the last 24 hours and down -3.94% over the past month.
Cybin Inc., a biotechnology company, focuses on developing psychedelic therapeutics to treat various psychiatric and neurological conditions. The company operates through two segments, Serenity Life and Cybin U.S., and Natures Journey. The Serenity Life and Cybin U.S. segment engages in the research and development of psychedelic pharmaceutical products. The Natures Journey segment focuses on non-psychedelic medicinal mushroom nutraceutical products. It develops CYB001, a drug candidate that is in phase IIa/b for major depressive disorder; CYB003, a deuterated tryptamine preclinical program to treat alcohol use disorder; CYB004, a deuterated tryptamine preclinical program for therapy resistant psychiatric disorder; and CYB005, a phenethylamine preclinical program for psychiatry and neurology. The company offers its products through various form factors, such as capsules, powders, and effervescent tablets. Cybin Inc. is headquartered in Toronto, Canada.
See More
Previous Close:
$6.02
Open:
$5.98
24h Volume:
360.14K
Relative Volume:
0.65
Market Cap:
$138.00M
Revenue:
-
Net Income/Loss:
$-52.07M
P/E Ratio:
-28.17
EPS:
-0.2077
Net Cash Flow:
$-44.93M
1W Performance:
-9.02%
1M Performance:
-3.94%
6M Performance:
-13.97%
1Y Performance:
-40.18%
1-Day Range:
$5.83
$6.025
1-Week Range:
$5.83
$6.40
52-Week Range:
$4.81
$13.88
Cybin Inc Stock (CYBN) Company Profile
Name
Cybin Inc
Sector
Industry
Phone
908 764 8385
Address
100 King Street West, Suite 5600, Toronto
Compare CYBN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CYBN
Cybin Inc
|
5.85 | 151.63M | 0 | -52.07M | -44.93M | -0.2077 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Cybin Inc Stock (CYBN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-25 | Initiated | Guggenheim | Buy |
| Nov-19-21 | Downgrade | Maxim Group | Buy → Hold |
Cybin Inc Stock (CYBN) Latest News
Sector ETF performance correlation with Cybin Inc.Treasury Yields & Technical Pattern Based Buy Signals - newser.com
What hedge fund activity signals for Cybin Inc. stockMarket Weekly Review & Safe Capital Growth Trade Ideas - newser.com
Has Cybin Inc. found a price floor2025 Earnings Impact & Fast Gaining Stock Reports - newser.com
Can Cybin Inc. stock deliver surprise earnings beatJuly 2025 Update & Free Long-Term Investment Growth Plans - newser.com
Is Cybin Inc. stock oversold or undervalued2025 Price Action Summary & Free Technical Pattern Based Buy Signals - newser.com
Will Cybin Inc. rebound enough to break evenJuly 2025 Update & Accurate Technical Buy Alerts - newser.com
What technical models suggest about Cybin Inc.’s comeback2025 Stock Rankings & Community Consensus Stock Picks - newser.com
Is Cybin Inc. stock a safe buy before earningsWeekly Market Outlook & Low Risk High Win Rate Stock Picks - newser.com
How institutional ownership impacts Cybin Inc. stockQuarterly Growth Report & Verified Trade Idea Suggestions - newser.com
Advanced analytics toolkit walkthrough for Cybin Inc.Portfolio Risk Report & Entry Point Confirmation Alerts - newser.com
What institutional flow reveals about Cybin Inc.Weekly Investment Summary & Low Risk High Reward Trade Ideas - newser.com
Key metrics from Cybin Inc.’s quarterly dataInsider Selling & Consistent Profit Alerts - newser.com
Can Cybin Inc. Common Shares stock sustain double digit ROEJuly 2025 Opening Moves & Reliable Price Action Trade Plans - newser.com
Is Cybin Inc. (R7E) stock a fit for income portfoliosJuly 2025 Outlook & Long-Term Investment Growth Plans - newser.com
Reversal indicators forming on Cybin Inc. stockJuly 2025 Macro Moves & Stepwise Trade Signal Implementation - newser.com
Cybin Inc Stock Analysis and ForecastBear Market Strategies & Small Investment Portfolio Growth - earlytimes.in
Facet Life Sciences Partners with Cybin to Advance Mental Health Therapies - MSN
Will Cybin Inc. (R7E) stock profit from automation waveWeekly Risk Report & AI Based Buy and Sell Signals - newser.com
Understanding Cybin Inc.’s price movementMarket Volume Report & Capital Efficient Trading Techniques - newser.com
Using Ichimoku Cloud for Cybin Inc. technicalsWeekly Trade Recap & High Accuracy Trade Alerts - newser.com
Relative strength of Cybin Inc. in sector analysisTrade Signal Summary & Daily Profit Focused Stock Screening - newser.com
Why retail traders accumulate Cybin Inc. (R7E) stock2025 Institutional Moves & Weekly Setup with High ROI Potential - newser.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cybin Inc.CYBN - Eastern Progress
Cybin Inc. stock daily chart insightsMarket Risk Analysis & Weekly Watchlist of Top Performers - newser.com
How geopolitical tensions affect Cybin Inc. stockQuarterly Profit Report & Reliable Intraday Trade Alerts - newser.com
Can Cybin Inc. recover in the next quarterBuy Signal & Fast Entry Momentum Alerts - newser.com
Intraday pattern recognizer results for Cybin Inc.M&A Rumor & Low Volatility Stock Suggestions - newser.com
Is Cybin Inc a good long term investmentFibonacci Retracement Levels & Stocks With 200% Upside Potential - earlytimes.in
Cybin Inc Stock (CYBN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
Cap:
|
Volume (24h):